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DOES SIZE MATTER? NANOSCALE PARTICLE
SIZE AS AN INDICATOR OF INHERENCY IN
NANOPHARMACEUTICAL PATENT VALIDITY
Kirsten E. Fehlan*
ABSTRACT
Scientific and technological advances in nanopharmaceuticals
bring the doctrine of inherent obviousness to a head. On the one hand,
nanotechnology promises to offer novel ways to target and treat
traditionally incurable diseases by operating at a scale that is
comparable to the scales that most biological systems use. On the
other hand, nanotechnology inventions that result in improved
pharmacokinetic properties are susceptible to validity challenges
based on inherent obviousness.
Inherency and obviousness are two independently recognized and
well-understood principles in United States patent law. Inherency
refers to a claimed limitation or feature that is either necessarily
present in, or the natural result of, the features expressly disclosed by
the prior art. Obviousness, in contrast, refers to whether the claimed
invention as a whole was readily apparent in the prior art based on a
combination of references. Because inherency turns on whether
something was necessarily present in the prior art at some earlier time,
the analysis implicates hindsight. But because obviousness turns on
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what would have been obvious to a person having ordinary skill in the
art at the time the invention was made, the analysis forbids hindsight.
Despite the seemingly mutual exclusivity between inherency and
obviousness, the two principles have been increasingly applied
together in the context of pharmaceutical and biotechnology
inventions. Patent challengers frequently rely on the argument that
improved pharmaceutical concentration and bioavailability at the
target site is implicit in prior art teachings concerning how
pharmaceutical particles behave at decreased sizes despite the novelty
of the particle’s size alone. Rather than engage in an arbitrary
analysis focusing on how unexpected some pharmacokinetic response
is, courts and the USPTO should eradicate the concept of inherent
obviousness in its entirety.
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INTRODUCTION
Within the last thirty years, nanotechnology has emerged as a viable
approach to overcome historically insurmountable technological
deficits apparent in a variety of traditional scientific applications. 1
Nanotechnology refers to the design, production, or modification of
structures, devices, or systems at the nanoscale (<100 nm).2 Recently,
nanotechnology has been used to investigate how structures
engineered with nanomaterials interact with biological systems, like
the human body.3 Accordingly, nanotechnology, when applied as
clinical nanomedicine, offers a promising approach for treating,
diagnosing, or preventing historically untreatable diseases through the
design and development of pharmaceutical nanoparticles
(nanopharmaceuticals) to drive targeted drug delivery.4 When
compared to conventional drug delivery, nanoparticle-mediated drug
delivery increases pharmaceutical concentrations in targeted cells
relative to non-targeted cells, thereby decreasing symptoms of
unfavorable side effects associated with the administered drug.5 That
said, nanotechnology’s promising impact in clinical medicine collides
with patentability challenges at the commercialization stage, where the
process of converting basic nanopharmaceutical research into
commercially viable products has been “difficult.”6 Despite this

1. Alexandre Albanese, Peter S. Tang & Warren C. W. Chan, The Effect of Nanoparticle Size, Shape,
and Surface Chemistry on Biological Systems, 14 ANN. REV. BIOMEDICAL ENG’G 1, 2 (2012).
Nanotechnology research focuses on the association between nanomaterial properties (optical, electrical,
and magnetic) “with respect to their size, shape, and surface chemistry.” Id.
2. Id.
3. Id.
4. See id.; see also Domenico Cassano, Salvador Pocoví-Martínez & Valerio Voliani,
Ultrasmall-in-Nano Approach: Enabling the Translation of Metal Nanomaterials to Clinics, 29
BIOCONJUGATE CHEMISTRY 4, 4 (2018). Nanomedicine is the application of nanotechnology in the
medical context. Id. For example, some of these medical applications include small-scale drugs in the
form of nanoparticles or medical devices in the form of cell-repairing nanorobots. See id.; see also Jordan
Paradise, Claiming Nanotechnology: Improving USPTO Efforts at Classification of Emerging
Nano-Enabled Pharmaceutical Technologies, 10 NW. J. TECH. & INTELL. PROP. 169, 169 (2012).
5. See Raj Bawa, Srikumaran Melethil, William J. Simmons & Drew Harris, Nanopharmaceuticals:
Patenting Issues and FDA Regulatory Challenges, 5 SCITECH LAW., no. 2, Fall 2008, at 1, 2. See generally
Albanese et al., supra note 1.
6. Raj Bawa, M.S., Ph.D., FAAN, Nanotechnology Patent Proliferation and the Crisis at the U.S.
Patent Office, 17 ALB. L.J. SCI. & TECH. 699, 719 (2007).
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difficulty, however, viable commercialization depends on securing
valid patent protection first.7
Patent law––one of the “most obscure legal disciplines”––sits on the
front line of modern drug development.8 To be patentable, an invention
must be novel as well as useful, nonobvious, and compliant with
patentability statutory requirements.9 This fundamental principle of
patent law favors patent validity unless the claimed invention covers
unpatentable subject matter or has been previously disclosed by one or
more prior art references.10 Prior art references, however, need not
disclose every limitation of the claimed invention. 11 Rather, prior art
that fails to explicitly disclose the claimed invention nevertheless
precludes patentability when a feature of the claimed invention
7. Bawa et al., supra note 5, at 5.
8. Id. at 3.
9. 35 U.S.C. §§ 102, 103. The relevant portions of 35 U.S.C. § 102 provide:
(a) NOVELTY; PRIOR ART.—A person shall be entitled to a patent unless—
(1) the claimed invention was patented, described in a printed publication, or in
public use, on sale, or otherwise available to the public before the effective filing
date of the claimed invention; or
(2) the claimed invention was described in a patent issued under section 151, or in
an application for patent published or deemed published under section 122(b), in
which the patent or application, as the case may be, names another inventor and
was effectively filed before the effective filing date of the claimed invention.
§ 102.
The relevant portions of 35 U.S.C. §103 provide:
A patent for a claimed invention may not be obtained, notwithstanding that the
claimed invention is not identically disclosed as set forth in section 102, if the
differences between the claimed invention and the prior art are such that the
claimed invention as a whole would have been obvious before the effective filing
date of the claimed invention to a person having ordinary skill in the art to which
the claimed invention pertains. Patentability shall not be negated by the manner in
which the invention was made.
§ 103.
10. Bawa et al., supra note 5, at 3–4. Prior art is any evidence that tends to indicate the claimed
invention is already publicly known. What Is Prior Art?, EUR. PAT. OFF.,
https://www.epo.org/learning/materials/inventors-handbook/novelty/prior-art.html
[https://perma.cc/X5DY-V6CR]. Prior art need not be a tangible product because many inventions never
become products; however, there might be evidence of that invention. See id. Common examples of prior
art include previous patent applications, scientific articles, or a prior sale of the claimed invention. See
U.S. PAT. & TRADEMARK OFF., MANUAL OF PATENT EXAMINING PROCEDURE § 2152, at 2100-356 (rev.
9th ed. 2020) (citations omitted); see also Michael Goldman, Georgia Evans & Andrew Zappia, Inherent
Anticipation in the Pharmaceutical and Biotechnology Industries, 5 COLD SPRING HARBOUR PERSPS.
MED.
1,
2–3
(2015),
http://perspectivesinmedicine.cshlp.org/content/5/8/a021006.full.pdf
[https://perma.cc/R9ET-GVWR].
11. See §§ 102, 103.
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necessarily flows from the prior art.12 Nanopharmaceuticals present a
unique patentability challenge because a decrease in particle size
significantly impacts the compound’s molecular properties, like
biologic distribution (or biodistribution); however, whether the
resultant molecular properties necessarily flow from the larger version
of that compound remains unclear.13 Yet with no clear direction from
the Federal Circuit, pharmaceutical companies and research
institutions are left wondering whether modifying particle size at the
nanoscale renders inherent the biological effects resulting from a
decrease in size.14
Companies either seeking a nanotechnology patent or attempting to
enforce a nanotechnology patent share a common problem: patent
uncertainty.15 One obstacle to enforcing nanotechnology and
nanopharmaceutical patents, in general, concerns whether a claimed
limitation of a nanoparticle composition necessarily flows from, or is
inherently present in, the prior art.16 Although courts generally agree
that properties resulting from a decrease in particle size are inherent,
at a minimum, courts should cautiously apply the inherency doctrine
when evaluating the validity of nanopharmaceutical patents.
12. Goldman et al., supra note 10, at 3. For example, if the prior art product (or composition), “in its
normal and usual operation would necessarily perform” the claimed method, then the prior device teaches
the claimed method. U.S. PAT. & TRADEMARK OFF., supra note 10, § 2112.02, at 2100-140. Further, if
the invention claims a method of producing positron-emitting rubidium-82 for use in positron emission
tomography (PET) scans by encouraging electron capture (which subsequently overcomes any subject
matter eligibility hurdle), a prior disclosure of strontium-82 for use in PET scans will likely bar
patentability even if that disclosure is silent as to electron capture because strontium-82 naturally produces
rubidium-82 after decaying by electron capture; thus, rendering the electron capture limitation necessarily
or inherently present in the prior art. See, e.g., BRACCO DIAGNOSTICS, CARDIO GEN-82 RUBIDIUM RB 82
GENERATOR (2000), http://www.nuclearonline.org/PI/Cardiogen.pdf [https://perma.cc/7UNJ-GTHN].
13. See Albanese et al., supra note 1, at 8; see also Par Pharm., Inc., v. TWi Pharms., Inc., 773 F.3d
1186, 1186 (Fed. Cir. 2014).
14. Bawa, supra note 6, at 728–29. The Federal Circuit, otherwise known as the United States Court
of Appeals for the Federal Circuit, is the only appellate level court with jurisdiction to hear patent case
appeals, other than the Supreme Court. Court Jurisdiction, U.S. CT. OF APPEALS FOR THE FED. CIR.,
http://www.cafc.uscourts.gov/the-court/court-jurisdiction [https://perma.cc/Y6FK-EF2M]. In Par
Pharmaceutical, Inc. v. TWi Pharmaceuticals., Inc., the Federal Circuit laid out the proper analysis for
evaluating inherent obviousness under 35 U.S.C. § 103 but remanded the case back to the district court
for a ruling. TWi Pharms., Inc., 773 F.3d at 1193–94, 1200.
15. See Bawa et al., supra note 5, at 4; see also Bawa, supra note 6, at 730. This uncertainty arises as
a result of overly broad pharmaceutical patent claims, that leave pharmaceutical companies unsure of how
far the scope of their patent claims extends. Bawa, supra note 6, at 730.
16. TWi Pharms., Inc., 773 F.3d at 1195–96.
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This Note proceeds in the following three parts. First, Part I provides
a general introduction to the structure and function of
nanopharmaceuticals and the law governing their patentability.17
Second, Part II investigates and analyzes the current state of U.S. case
law concerning nanopharmaceutical patent challenges based on
inherency.18 Finally, Part III proposes that courts should rethink the
inherency standard as it applies to nanopharmaceutical patents––or
eliminate it altogether.19
I. BACKGROUND
Nanotechnology is “the design, characterization, production and
application of structures, devices and systems” by modifying shape
and size of matter at the nanoscale.20 Because nanotechnology simply
refers to manipulating matter on an atomic, molecular, or
supramolecular scale, the application of nanotechnology within each
respective scientific field is equally diverse. 21 Accordingly,
nanotechnology defined by size encompasses a naturally broad range
of scientific fields and disciplines, including molecular biology,
surface science, electrical engineering, semiconductor physics, and
more.22
One
application
of
nanotechnology––namely,
nanomedicine—refers to the medical application of nanotechnology. 23
17. See infra Part I.
18. See infra Part II.
19. See infra Part III.
20. Albanese et al., supra note 1; But what constitutes nanoscale depends on the source. Cephalon,
Inc. v. Abraxis Bioscience, LLC, 618 F. App’x 663, 665 (Fed. Cir. 2015) (“1000 nanometers”); Paradise,
supra note 4, at 193 (“[U]nder 100 nm.”).
21. Nanotechnology, CTRS. FOR DISEASE CONTROL & PREVENTION, NAT’L INST. FOR OCCUPATIONAL
SAFETY
&
HEALTH
(NIOSH),
https://www.cdc.gov/niosh/topics/nanotech/default.html
[https://perma.cc/HK3C-2Y7L] (Mar. 27, 2020); see also W. JONES & C. N. R. RAO, SUPRAMOLECULAR
ORGANIZATION AND MATERIALS DESIGN 34–35 (2002). The supramolecular scale refers to an area of
chemistry concerning chemical systems composed of a discrete number of molecules. See id. A molecule
is “an electrically neutral group of two or more atoms held together by [a] chemical bond[]” or bonds.
2.6:
Atoms
and
Molecules–
Real
and
Relevant,
CHEMISTRY
LIBRETEXTS,
https://chem.libretexts.org/Courses/Sacramento_City_College/SCC%3A_CHEM_330__Adventures_in_Chemistry_(Alviar-Agnew)/02%3A_Atoms/2.06%3A_Atoms_and_Molecules_Real_and_Relevant [https://perma.cc/C2LX-JXAW] (Sept. 24, 2021).
22. See Nanotechnology, supra note 21.
23. ROBERT A. FREITAS, NANOMEDICINE, VOLUME I: BASIC CAPABILITIES 1, 25–26 (1999),
http://kriorus.ru/sites/kriorus/files/nanomed/NANOMEDI.PDF [https://perma.cc/D65R-2AQT].
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Nanomedicine encompasses a broad application of nanotechnology
via the design and development of nanomaterials, biological devices,
nanoelectric biosensors, and biological machines.24 Recent trends in
experimental nanomedicine have focused on examining the interaction
between nanomaterials and biological systems, thereby paving the way
for novel developments in targeted drug delivery through
nanoparticles.25
The “unique” and “far-ranging properties” attributed to
nanoparticles have already facilitated major breakthroughs in the
pharmaceutical industry, which raked in $16 billion on nanomedicine
sales in 2015 alone. 26 But success comes at a high price. Because of
the high-risk, high-reward nature of the pharmaceutical industry––
which is characterized by exceedingly high research and development
(R&D) costs, lengthy clinical trials and data generation periods, and
intense competition among pharmaceutical market participants—
patents are a key ingredient for commercial success due to their
promise for market exclusivity.27
The possibility for commercial success with nanopharmaceutical
and nanoparticle-mediated drug delivery systems inspired an influx of
patent applications at the United States Patent and Trademark Office

24. See Francisco T.T. Cavalcante, Italo R. de A. Falcão, José E. da S. Souza, Thales G. Rocha,
Isamayra G. de Sousa, Antônio L. G. Cavalcante, André L. B. de Oliveira, Maria C. M. de Sousa & José
C.S. dos Santos, Designing of Nanomaterials-Based Enzymatic Biosensors: Synthesis, Properties, and
Applications, 2 ELECTROCHEM 149, 152 (2021).
25. See Albanese et al., supra note 1. Targeted drug delivery reduces overall drug consumption by
increasing pharmaceutical concentrations at the targeted intracellular site and subsequently reduces
negative side effects because of this overall reduction in drug consumption. See Timothy S. Tracy,
Pharmacokinetics, in MODERN PHARMACOLOGY WITH CLINICAL APPLICATIONS 48, 49–52 (Charles R.
Craig & Robert E. Stitzel eds., 6th ed. 2004).
26. See Paradise, supra note 4; Market Report on Emerging Nanotechnology Now Available, NAT’L
SCI. FOUND. (Feb. 25, 2014), https://www.nsf.gov/news/news_summ.jsp?cntn_id=130586
[https://perma.cc/A7SR-CKM9]; see also Cornelia Vasile, Polymeric Nanomaterials: Recent
Developments, Properties and Medical Applications, in POLYMERIC NANOMATERIALS IN
NANOTHERAPEUTICS 36 (Cornelia Vasile ed., Elsevier 2018) (“Nanomedicine sales reached $16 billion
in 2015, with a minimum of $3.8 billion in nanotechnology R&D invested every year.”). For example,
Abraxane®, a drug used for the treatment of breast cancer, netted $848 million from sales in 2014 alone.
Press Release, Celgene, Celgene Corporation Announces 2015 and Long-Term Financial Outlook and
Preliminary 2014 Results (Jan. 12, 2015) (on file with the Georgia State University Law Review).
27. See Paradise, supra note 4; see also Michael Berger, Nanotechnology Patents and the Future of
the
Pharma
Industry,
NANOWERK
(Oct.
12,
2007),
https://www.nanowerk.com/spotlight/spotid=2912.php [https://perma.cc/U74Z-KKBU].

https://readingroom.law.gsu.edu/gsulr/vol38/iss3/14

8

Fehlan: Nanoscale Particle Size as an Indicator

2022]

DOES SIZE MATTER?

1065

(USPTO) that continues in full force to date.28 Rather than succumb to
this influx of nanopharmaceutical patent applications, however, the
USPTO did exactly as it does: It granted patents.29 With no formal
classification system to fully encompass novel nanotechnologies, the
USPTO granted overly broad patent claims. 30 Broad
nanopharmaceutical patent claims coupled with nanotechnology’s
promise to be the “next frontier” in health care is likely to trigger
needless patent litigation because these products are just now
beginning to reach commercialization stage. 31 With the added
uncertainty that many pharmaceutical companies and research
institutions face concerning whether far-reaching claims from earlier
patents overlap with theirs, validity disputes are almost certain. The
Federal Circuit had a chance to resolve this uncertainty. Yet the
Federal Circuit’s decision (or lack thereof) in Par Pharmaceutical, Inc.
v. TWi Pharmaceuticals, Inc., merely left many companies and
universities wondering whether biological effects resulting from
modifications in particle size at the nanoscale are inherently disclosed
in prior art.32
A. Vehicles of Drug Delivery: How Do Nanopharmaceuticals Even
Work?
Before the sophisticated structural components of nanoparticles can
be appreciated, it is important to first understand how pharmaceuticals
exert their biological effect. In any biological system, compound
structure determines function, and nanoparticles are no exception to
this well-established rule.33 Nanopharmaceuticals work to increase
pharmaceutical bioavailability at their on-site targets by improving
pharmacokinetic and pharmacodynamic effects. 34 To produce an
effect, a pharmaceutical particle binds to and interacts with specialized
28. See Paradise, supra note 4, at 191.
29. See Bawa et al., supra note 5, at 723.
30. See id. at 724.
31. See Paradise, supra note 4, at 169–70.
32. See generally Par Pharm., Inc., v. TWi Pharms., Inc., 773 F.3d 1186, 1186 (Fed. Cir. 2014).
33. See generally JONES & RAO, supra note 21. Shape and size are equally important. See id. at 36.
34. See ROBERT M. JULIEN, CLAIRE D. ADVOKAT & JOSEPH E. COMATY, A PRIMER OF DRUG ACTION
3–4, 36 (12th ed. 2010).
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cellular surface receptors. 35 Particle binding leads to changes in a cell’s
functional properties, which result in the drug’s signature
pharmacologic response. 36 The strength of this attachment is
determined by how the drug’s three-dimensional structure fits with the
receptor’s three-dimensional site.37 Importantly, even modest
variations in a particle’s chemical structure greatly influence the
receptor’s response to it.38
A drug’s “total action” is measured by its pharmaceutical response
at either a single receptor type or at a collection of different receptor
types, depending on that drug’s target specificity.39 In either scenario,
drug-receptor binding alters cellular function and subsequently
produces observable physiological or psychological effects—a result
of the drug’s total action.40 Irrespective of whether the total action
results from binding at one receptor site or a collection of sites,
unavoidable side effects persist.41 Because nanoparticle-mediated
delivery requires a smaller dose to achieve the same therapeutic effect,
overall drug consumption is lowered and unavoidable side effects are
less likely.42

35. Id. at 36. Receptors are relatively large (usually protein) molecules that sit on or within a cell. Id.
at 38. Each receptor contains naturally occurring endogenous compounds, known as transmitters or
modulators, that produce their biologic effects. Id. It is important to note that not all specialized receptors
are located on cell members. Id. Some intracellular receptors located in the cytoplasm or nucleus are
activated by small, hydrophobic ligand molecules. See id. at 38–49.
36. Id. at 36.
37. Id. at 36–37.
38. See id. at 37.
39. Id. at 50.
40. JULIEN ET AL., supra note 34, at 36–37, 50.
41. See id. at 50. Side effects refer to the additional responses of a particle’s “total action” and limit a
drug’s efficacy when intolerable. Id. Against common belief, not all side effects are bad. See id. But
investigating all the beneficial “effects” of side effects is beyond the scope of this Note.
42. Ramya Ranganathan, Shruthilaya Madanmohan, Akila Kesavan, Ganga Baskar, Yoganathan
Ramia Krishnamoorthy, Roy Santosham & D. Ponraju et al., Nanomedicine: Towards Development of
Patient-Friendly Drug-Delivery Systems for Oncological Applications, 7 INT’L J. NANOMEDICINE 1043,
1058 (2012).
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B. A “Small” Introduction to Nanopharmaceuticals
Nanopharmaceuticals are colloidal particles ranging in size from ten
to one thousand nanometers.43 The smallest component of
nanopharmaceuticals are nanoparticles, which result from combining
active molecules or biological substances to enhance targeted drug
delivery by the subsequent release of pharmaceutical agents at the
targeted site.44 One of the greatest advantages to
nanoparticle-mediated drug delivery is a nanoparticle’s ability to
quietly bypass a biological system’s natural immune response and
continue on to its target.45
Cell-specific targeting is characterized by attachment of a
pharmaceutical compound to specially designed carriers:
nanoparticles.46 Various nanomaterials may be used for nanoparticle
construction—including polymers, liposomes, dendrimers, carbon
materials, and even gold—and the nanomaterial used for construction
consequently influences the nanoparticle’s properties.47 The properties
of each particular nanomaterial have a differential effect on the
nanoparticle’s behavior within the biological system. 48 Differences in

43. Bawa et al., supra note 5, at 1–2. Yet it is critically important to note that the size range used to
quantify a particle as a nanoparticle is inconsistent. See id.
44. See id. A typical nanoparticle is produced via chemical synthesis and coated with polymers, drugs,
fluorophores, peptides, proteins, or oligonucleotides. Albanese et al., supra note 1, at 3.
45. See Syed A. A. Rizvi & Ayman M. Saleh, Applications of Nanoparticle Systems in Drug Delivery
Technology, 26 SAUDI PHARM. J. 64, 65 (2018). A detailed discussion of immune functioning is beyond
the scope of this Note, but it is important to mention that once a drug enters the circulation system, it is
subject to detection by the lymphatic system. Id. If detected, macrophages will “engulf” (essentially kill)
the exogenous matter. See id. Conventional forms of drug delivery systems generally rely on
administering higher doses of a drug to achieve a therapeutic effect, whereas nanoparticle-mediated drug
delivery systems rely on a smaller dose and even high therapeutic effect. Id.
46. See Agnieszka Z. Wilczewska, Katarzyna Niemirowicz, Karolina H. Markiewicz & Halina Car,
Nanoparticles as Drug Delivery Systems, 64 PHARMACOLOGICAL REPS. 1020, 1020–21 (2012).
47. Id. at 1021; KAYE SCHOLER LLP, PHARMACEUTICAL AND BIOTECH PATENT LAW § 2:4.1(A), at
2-9 (David K. Barr & Daniel L. Reisner eds., 2015). Further, nanomaterials may be grouped according to
their mechanical properties. Id. When classified by mechanical properties, polymers, lipid vesicles,
dendrimers, and polymer-protein conjugates are at the “soft” end, while inorganic materials are at the
“hard” end. See Cassano et al., supra note 4.
48. See generally Cassano et al., supra note 4; JULIEN ET AL., supra note 34, at 36. Pharmacodynamics
concern the movement of drugs through the body, whereas pharmacodynamics concerns the body’s
biological response to those drugs. Id. at 36. Pharmacokinetics describe a drug’s efficacy by characterizing
its absorption, distribution, bioavailability, metabolism, or excretion as a function of time. See id. at 3–4.
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nanomaterials also promote targeted nanoparticle delivery by
interacting with cell surface biomolecules to promote cellular uptake. 49
The “efficacy of most drug delivery systems is directly related to
particle size.”50 Particle size is defined by the particle’s mean diameter
(in nanometers) or specific surface area (SSA).51 In general,
nanoparticles have a mean diameter under 100 nanometers, in
comparison to their microparticle counterparts; however, many
nanoparticle sizes tend to exceed 100 nanometers.52 The 100
nanometer ceiling refers to the size at which nanomaterial properties
tend to significantly change from their conventional and functional
analogs.53 Nevertheless, changing a compound’s particle
size—whether micro to nano or nano to micro—often, unpredictably
and fundamentally, changes that particle’s molecular properties.54 “As
a particle’s size decreases, a [higher] proportion of its atoms” relocate
to the particle’s surface relative to its core. 55 The result is an increase

49. See Wilczewska et al., supra note 46, at 1021. A particle with a large surface area in the
pharmaceutical realm is advantageous for that particle’s subsequent affinity for drugs and small
molecules, such as ligands or antibodies. See id. For example, coating a nanoparticle in a copolymer such
as polyethylene glycol (PEG) enhances delivery because of the hydrophilic properties that are responsible
for assisting the particle in stealthily passing by the lymphatic system. Rizvi & Saleh, supra note 45, at
66. PEG is a hydrophilic and relatively inert polymer that alters the binding ability of blood plasma
proteins to bypass detection and remain in circulation longer. Id. In fact, PEG remains undetected so long
as plasma proteins fail to bind to it. See id.
50. Id. at 65.
51. See KAYE SCHOLER LLP, supra note 47. Notably, one (1) micron is equivalent to 10-6 or 0.000001
meters. What is the Nanoscale–Size and Scale, UNIV. WIS.-MADISON, MRSEC EDUC. GRP.
https://education.mrsec.wisc.edu/what-is-the-nanoscale-size-and-scale/ [https://perma.cc/4ZHV-WC7J].
52. See THOMAS R. GILBERT, REIN V. KIRSS, NATALIE FOSTER, STACEY LOWERY BRETZ &
GEOFFREY DAVIES, CHEMISTRY: THE SCIENCE IN CONTEXT 590–91 (W. W. Norton & Co., Inc., 5th ed.
2018). One hundred nanometers is equivalent to 1 x 10-7 meters. Id. at 591.
53. Luigi Battaglia & Elena Ugazio, Lipid Nano- and Microparticles: An Overview of Patent-Related
Research, 2019 J. NANOMATERIALS 1, 10 (2019). But cutting off nanoparticle classification at 100
nanometers may not tell the full story when the desired or ideal property (i.e., bioavailability, low toxicity,
etc.) may be achieved at a larger size range. See Raj Bawa, Ph.D., Will the Nanomedicine “Patent Land
Grab” Thwart Commercialization?, 1 NANOMEDICINE: NANOTECHNOLOGY, BIOLOGY & MED. 346, 346
(2005); see also Bawa et al., supra note 5, at 2 (“Because there is no universal convention or nomenclature
that classifies nanopharmaceuticals, various nanoscale structures of different shapes are sometimes
classified as nanopharmaceuticals.”).
54. KAYE SCHOLER LLP, supra note 47. For example, micronizing the particles of a compound
increases a particle’s surface area, thereby altering properties such as solubility and processability. See id.
55. Bawa et al., supra note 5. As a result, the particle is more reactive and more soluble in water. Id.
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in surface area and solubility. 56 But even more important is the
resulting increase in bioavailable drug at the target site—the hallmark
of nanoparticle efficacy. 57
Nanoparticles’ newfound efficacy has the potential to alter the
current landscape of medicine, and pharmaceutical companies are
beginning to reap the benefits of this technology by seeking patent
protection.58 It follows that the future of nanomedicine depends on
securing patent protection and intellectual property rights.59
C. A Non-Technical Primer on Inherency
To be patentable, an invention must be novel, nonobvious, useful,
and comply with the statutory subject-matter requirements.60 First, the
novelty requirement ensures that the claimed invention is truly
“novel,” or the first.61 For a single prior art reference to anticipate (or
render invalid) a claim under 35 U.S.C. § 102, the reference must
disclose every limitation set forth in the claim.62 Second, the
56. See id.; see also Rizvi & Saleh, supra note 45. Increasing the surface area of a particle increases
solubility because surface area increases as particles are broken down and, consequently, more are in
contact with the solvent. See id. It may be helpful to think about the relationship between surface area and
solubility as this: Imagine a sugar cube; it is a solid, singular cube. But if the sugar cube were crushed,
the surface area would subsequently increase, and what was once a sugar cube would begin to spread out
as a powder. Rather than a mound of sugar, there is a generous blanket of sugar. The surface area of this
“sugar blanket” is larger than the cube, and it will surely dissolve quicker than the larger cube because
more of its atoms are on the surface. This is the solubility component.
57. See id.
58. Berger, supra note 27. For example, improvements in target specificity potentially address unmet
medical needs, like effective chemotherapy agents, and these improvements in target specificity are only
made possible by utilizing unique nanoparticle-mediated drug-delivery systems. Id.
59. See id. Many pharmaceutical companies utilize business models that rely on patent protection for
blockbuster drugs. Id. Accordingly, securing a patent on each research breakthrough is critical to
eventually commercializing and marketing a new product. Id.
60. See 35 U.S.C. §§ 102(a), 103.
61. Anticipation,
CORNELL
L.
SCH.,
LEGAL
INFO.
INST.,
https://www.law.cornell.edu/wex/anticipation#:~:text=Anticipation%20is%20a%20grounds%20for,was
%20invented%20by%20the%20patentee [https://perma.cc/G2N2-L2T3].
62. § 102(a). A prior art reference is evidence that the claimed invention is already known. What Is
Prior Art?, supra note 10. See, e.g., §§ 102(a), 103; JANICE M. MUELLER, PATENT LAW 229–30 (5th ed.
2016). In other words, the invention was known or used by others before the patent applicant filed an
application for the claimed invention. See, e.g., §§ 102(a), 103; MUELLER, supra. When every claimed
limitation is known, used, or at least reasonably accessible to the public, then that prior disclosure is said
to anticipate the claim. See, e.g., §§ 102(a), 103; MUELLER, supra. Claim elements and claim limitations
work together. See, e.g., WORLD INTELL. PROP. ORG. (WIPO), PATENT CLAIM FORMAT AND TYPES OF
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nonobvious requirement turns on whether a person with ordinary skill
or knowledge in the subject area would know to combine the features
disclosed in the prior art references to make the claimed invention. 63
For a reference to obviate a claimed invention under 35 U.S.C. § 103,
it must have been readily apparent to “a person having ordinary skill
in the art,” at the time of invention, to combine the features disclosed
by the prior art references to make the claimed invention.64 The
nonobvious requirement considers what a person having ordinary skill
in the art knew at the time of invention.65 Thus, retrospect is
impermissible.66 In essence, an invention that is obvious or not new
cannot be patented.

CLAIMS 13, 16 https://www.wipo.int/edocs/mdocs/aspac/en/wipo_ip_phl_16/wipo_ip_phl_16_t5.pdf
[https://perma.cc/XA4A-AKGB]. Claim elements are the named parts of the invention and can be thought
of as nouns that describe the physical structure of the invention. See Dennis Crouch, Query on Elements
and Limitations, PATENTLY-O (Mar. 17, 2009), https://patentlyo.com/patent/2009/03/query-on-elementsand-limitations.html [https://perma.cc/KCC4-66SN]. On the other hand, claim limitations are words or
phrases that describe the elements, and can be thought of as adjectives, adverbs, or other modifying
phrases. Id. For example, an issued patent or patent application may claim:
A [] device, comprising:
a handle;
a head portion connected to the handle; and
a protrusion being secured to the handle.
WORLD INTELL. PROP. ORG. (WIPO), supra, at 16. In this example, the handle, head portion, and
protrusion are claim elements that describe structural features of the claimed invention, while “connected
to the handle” and “secured to the handle” are claim limitations that describe the element to which they
are attached. Id.
63. Nonobviousness,
CORNELL
L.
SCH.,
LEGAL
INFO.
INST.
https://www.law.cornell.edu/wex/nonobviousness [https://perma.cc/LC8T-W5UA]. A claimed invention
is obvious if it is “readily apparent.” Id. It is worth noting, however, that in some rare circumstances, no
prior art reference is needed to obviate a claimed invention if the invention would have been readily
apparent to anyone with ordinary knowledge in the subject area at the time of invention. See id.
64. See, e.g., §§ 102(a), 103; see also, e.g., MUELLER, supra note 62, at 30. The term “person having
ordinary skill in the art,” or PHOSITA, is patent law jargon. See § 103. This hypothetical person refers to
an individual who has the same or similar skill level in a particular subject matter area that a standard
person in that subject matter area would have. See, e.g., §§ 102(a), 103; see also, e.g., MUELLER, supra
note 62, at 30. For example, if the invention refers to a chemical compound, a person having ordinary skill
in the art would most likely be a chemist having a Ph.D. in the area of chemical sciences most closely
related to the chemical compound (i.e., synthetic, organic, etc.). A claimed invention is usually obvious if
a person having ordinary skill in the art could make the claimed invention based on the relevant prior art.
Nonobviousness, supra note 63.
65. Id.
66. See U.S. PAT. & TRADEMARK OFF., supra note 10, § 2141.01, at 2100-262–2100-263 (“The
pre-AIA 35 U.S.C. 103(a) requirement ‘at the time the invention was made’ is to avoid impermissible
hindsight.” (quoting U.S. PAT. & TRADEMARK OFF., § 2145, at 2100-321)); see also U.S. PAT. &
TRADEMARK OFF., supra note 10, § 2145, at 2100-327.

https://readingroom.law.gsu.edu/gsulr/vol38/iss3/14

14

Fehlan: Nanoscale Particle Size as an Indicator

2022]

DOES SIZE MATTER?

1071

Where a prior art reference discloses a feature of the claimed
invention, the disclosure is usually express.67 But the disclosure need
not always be express.68 This is where inherency comes in. An inherent
feature may anticipate or obviate a claimed limitation even where that
feature’s existence was unknown in the prior art at the time it was
disclosed.69 A patent examiner or patent challenger relies on inherency
to supply a claim element absent in the prior art by showing the claim
element is “necessarily present” in the express subject matter of a prior
art reference.70 But because “inevitability is at the heart of
inherency[,]” the “fact that a certain thing may result from a given set
of circumstances” is insufficient to establish that it was inherent.71 It
follows that mere “probabilities or possibilities” cannot establish
inherency.72 Rather, a prior art reference or a combination of
references that teaches the “natural result flowing” from performing
the claimed limitation establishes inherency.73
Inherency is often invoked in cases involving patents related to
pharmaceuticals, biotechnology, life sciences, and now,
nanotechnology.74 These invocations typically arise in cases where an
inventor discovers “some previously unappreciated property” of a
product or process that is itself anticipated or obvious, but the inventor
nonetheless seeks to use this new discovery to patent the otherwise
67. Christopher Holman, Inherency in the Patenting of Biotechnology and Pharmaceutical
Innovation, 39. BIOTECHNOLOGY L. REP. 79, 79 (2020).
68. Id. (emphasis added).
69. Id.
70. Ryan Pool, The Inherency Doctrine: A Performance Review, 101 J. PAT. & TRADEMARK OFF.
SOC’Y 1000, 1000 (2019); Scaltech, Inc. v. Retec/Tetra, L.L.C., 178 F.3d 1378, 1384 (Fed. Cir. 1999).
See Schering Corp. v. Geneva Pharms., Inc., 339 F.3d 1373, 1377 (Fed. Cir. 2003); Atlas Powder Co. v.
Ireco, Inc., 190 F.3d 1342, 1348–49 (Fed. Cir. 1999). Parties use inherency arguments when the prior art
cited contains an incomplete description of the subject matter central to the dispute. See Scaltech, Inc.,
178 F.3d at 1382–84. For example, a prior art reference may disclose the claimed invention but may be
simply missing an element. See id. at 1383–84. The party objecting to the patent makes an inherency
argument to supply the element missing from the disclosure. See id.; see also Schering Corp., 339 F.3d at
1377; Atlas Powder Co., 190 F.3d at 1348–49.
71. Howmedica Osteonics Corp. v. Zimmer, Inc., 640 F. App’x 951, 957 (Fed. Cir. 2016); Scaltech,
Inc., 178 F.3d at 1384. It is insufficient that a certain thing may result from a given set of circumstances.
Howmedica Osteonics Corp., 640 F. App’x at 957.
72. Scaltech, Inc., 178 F.3d at 1384.
73. Continental Can Co. USA v. Monsanto Co., 948 F.2d 1264, 1268 (Fed. Cir. 1991) (quoting In re
Oelrich, 666 F.2d 578, 581 (C.C.P.A. 1981).
74. See Holman, supra note 67.
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anticipated or obvious subject matter.75 For example, a metabolite
produced by a patented compound cannot itself be subsequently
patented because that metabolite existed at the time the compound was
patented, whether or not anybody realized it. 76
Another common inherency issue relevant to pharmaceuticals arises
when a composition of matter, product, or apparatus is claimed in
terms of a property, characteristic, or function. 77 For example, if a prior
art reference teaches a chemical structure identical to one presently
claimed, it may be reasonable to assume (and argue) that the
characteristics or functions flowing from the claimed structure are
necessarily (or inherently) disclosed by the prior art because identical
structure indicates identical properties. 78 Similarly, product and
apparatus patents that claim features that are substantially identical to
prior art products, or that are produced by substantially identical
processes, could inherently disclose properties or functions disclosed
in the prior art reference.79 A prior art reference is more likely to
inherently disclose a feature claimed in terms of its function, property,
or characteristic––despite not expressly disclosing that feature’s
function, property, or characteristic––when compared to a feature
claimed in terms of its structure.80
The lines blur even more when inherency is used to obviate (rather
than anticipate) a claimed nanopharmaceutical invention. A person
having ordinary skill in the art need not recognize an inherent feature
at the time of invention irrespective of whether the inherent feature
75. Id.
76. See Schering Corp. v. Geneva Pharms., Inc., 339 F.3d 1373, 1375 (Fed. Cir. 2003). A metabolite
is a small molecule produced as an intermediate or end product of metabolism. Id.
77. Goldman et al., supra note 10, at 3.
78. This example presumes no differences between the two chemical structures concerning size,
function, and the like. See In re Spada, 911 F.2d 705, 708 (Fed. Cir. 1990) (“Products of identical chemical
composition can not have mutually exclusive properties.”); see also U.S. PAT. & TRADEMARK OFF., supra
note 10, § 2112.01, at 2100-139. Prior art that teaches a chemical structure, identical to the structure in a
present invention, also discloses properties that are necessarily present in that structure. U.S. PAT. &
TRADEMARK OFF., supra note 10, § 2112.01, at 2100-139.
79. See id.; see also In re Schreiber, 128 F.3d 1473, 1478 (Fed. Cir. 1997) (claimed conical-shaped
top for dispensing popcorn was the “same general shape” as the conical-shaped spout for dispensing oil
from a can in the prior art).
80. Goldman et al., supra note 10, at 3. Importantly, method of use claims may also utilize an
inherency argument where the use is directed to a result or to a property of known composition or
character. Id.
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was disclosed in the prior art.81 That said, an unrecognized feature in
the prior art can hardly be obvious. To the contrary, surprising results,
or results achieved by experimental accident, albeit inherent, are not
anticipated or obviated by a prior art reference. 82 Because the hallmark
of nanoparticle-mediated drug delivery is improved target specificity,
characterized by subsequent increases in bioavailability at the target
site, these new, improved drug-delivery systems and their
pharmacokinetic advancements often fall victim to inherency
challenges.83
81. U.S. PAT. & TRADEMARK OFF., supra note 10, § 2112, at 2100-136, 2100-137. Yet this contention
is seemingly contrary to the § 103 nonobviousness requirement, which is viewed from the perspective of
what a person of ordinary skill in the art knew at the time of invention. See id. (emphasis added) (“Where
applicant claims a composition in terms of a function, property or characteristic and the composition of
the prior art is the same as that of the claim but the function is not explicitly disclosed by the reference,
the examiner may make a rejection under both 35 U.S.C. 102 and 103.”). Older Federal Circuit cases
generally state that a prior art reference discloses the claimed invention if the missing element is
necessarily present in what is expressly described or taught by the reference and the inherent feature would
have been recognized by a person having ordinary skill in the art. Continental Can Co. USA v. Monsanto
Co., 948 F.2d 1264, 1268 (Fed. Cir. 1991) (emphasis added). But whether a person having ordinary skill
in the art would have recognized the inherent feature in the prior art was specifically addressed in Schering
Corporation v. Geneva Pharmaceuticals, where the Federal Circuit clarified that Continental Can does
not require past recognition of an inherent feature. See Schering Corp., 339 F.3d at 1378; Continental Can
Co. USA v. Monsanto Co., 948 F.2d 1264, 1269 (Fed. Cir. 1991). Artisans of ordinary skill may not
recognize inherent characteristics or functions in the prior art. Atlas Powder Co. v. Ireco, Inc., 190 F.3d
1342, 1347 (Fed. Cir. 1999). Yet essentially rediscovering a previously unappreciated property or function
of an old prior art composition “does not render the old composition patentably new. . . .” See id.; see also
Titanium Metals Corp. v. Banner, 778 F.2d 775, 782 (Fed. Cir. 1985) (“Congress has not seen fit to permit
the patenting of an old [composition], known to others . . . by one who has discovered its . . . useful
properties, or has found out to what extent one can modify the composition . . . without losing such
properties.”). But see Honeywell Int’l Inc. v. Mexichem Amanco Holding S. A. de C.V., 865 F.3d 1348,
1354 (Fed. Cir. 2017) (acknowledging that using inherency in an obviousness determination is more
complicated because “‘[t]hat which may be inherent is not necessarily known’ and that which is unknown
cannot be obvious.” (first alteration in original) (quoting In re Rijckaert, 9 F.3d 1531, 1534 (Fed. Cir.
1993)).
82. See, e.g., Tilghman v. Proctor, 102 U.S. 707, 711–12 (1880). But the result must not have been
appreciated or predicted by a person with ordinary skill or knowledge in the subject area in light of the
prior art. Id. at 723–24. Accidental results produced under unusual conditions or while in pursuit of “other
and different results, without . . . even being known what was done or how it had been done,” likewise do
not constitute inherent disclosures. Id. at 711–12 (noting that it would be “absurd” to consider this
anticipation (citation omitted)). Similarly, results that are occasionally obtained are not inherent. See
MEHL/Biophile Int’l Corp. v. Milgraum, 192 F.3d 1362, 1365 (Fed. Cir. 1999); see also In re Rijckaert,
9 F.3d at 1534 (no inherent disclosure where optimal conditions not disclosed implicitly or explicitly).
The distinction between accidental disclosure and failure to recognize an inherent limitation is one of
necessity, and the question becomes whether it is necessary that those who made or used the invention
disclosed in the prior art reference “actually recognized” at that time that the inherent feature existed. See
MUELLER, supra note 62, at 234–35 (emphasis added); see also 35 U.S.C. § 103.
83. See generally Holman, supra note 67.
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D. The Current Nanopharmaceutical Landscape
To date, the nanopharmaceutical patent landscape is “almost
impossible to navigate.”84 First, pharmaceutical companies and
research institutions continue to carve out “far-reaching” patent claims
in hopes of receiving a broad scope of patent protection. 85 As more
companies begin to enter commercialization stages, uncertainty lingers
around the scope of nanopharmaceutical patent protection and whether
the “far-reaching” claims from these early patents overlap with one
another.86
Second, only a limited number of judicial opinions exist concerning
nanotechnology patents and similarly ambiguous terminology in the
field.87 A targeted search for case law focusing primarily on
nanoparticle size or pharmaceuticals at the nanoscale reveals very few
patent-related disputes.88 But, because decreasing particle
size—thereby altering the structural characteristics––often impacts the
biological properties of a particle, the question of whether changes in
a particle’s properties (like biological effect) resulting from altering its
structural characteristics (like particle size) are inherently present in
prior art compositions remains unanswered. Although particles at the
microscale exhibit properties that are different from their chemical
equivalents at the nanoscale, prior case law concerning microparticles
hints at how courts may view patents claiming these conventional
pharmaceuticals at the nanoscale. 89 The next section discusses some of
the current case law addressing the question of whether new or

84. Bawa et al., supra note 5, at 4.
85. See id. (noting that the USPTO granted nanopatents of “questionable validity and scope”).
86. See id.
87. See id.
88. As of September 2020, a very general search (“nanoparticle” OR “nanoscale”) on LexisNexis’
state and federal cases retrieved eighty-one cases thatmention “nanoparticle” or “nanoscale” somewhere
in the text.
89. Battaglia & Ugazio, supra note 53, at 10 (“[One hundred] nm is the demarcating upper limit as it
refers to the size around which the properties of materials can change significantly from conventional
equivalents.”); See generally Apotex Inc. v. Cephalon, Inc., No. 2:06-cv-2768, 2011 U.S. Dist. LEXIS
125859 (E.D. Pa. Oct. 31, 2011); Cephalon, Inc. v. Abraxis Bioscience, LLC, 618 F. App’x 663 (Fed. Cir.
2015).
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improved properties observed at the nanoscale (or microscale) are
inherent in the prior art.90
II. ANALYSIS
Central to the inherency debate is whether modifications in particle
size are necessarily present in prior art. Although Par Pharmaceutical,
Inc. v. TWi Pharmaceuticals, Inc., sheds light on the appropriate
inherency analysis in the nanopharmaceutical context, the Federal
Circuit did not answer the question of when functional differences
resulting from reducing particle size from microscale to nanoscale
might be substantial enough to save the particle from an inherency
analysis.91 Additionally, the Federal Circuit Court only considered the
inherency question as it relates to nanoparticle properties in the context
of a method patent and not a composition-of-matter patent.92 This
section investigates whether modifications in particle size render a
previously valid patent invalid for inherent anticipation or inherent
obviousness.93
A. A Hint at Inherent Microparticles in the Context of a
Composition Claim
In Apotex Inc. v. Cephalon, Inc. (Apotex), the Court of Appeals for
the Federal Circuit held Cephalon’s claimed pharmaceutical
composition invalid because the pharmacokinetic properties at a 200
micron (µm) threshold were obvious in light of a previously
discovered compound.94 In this case, Apotex, a generic drug
manufacturer, challenged the validity of U.S.-based Cephalon’s U.S.
90. See generally Apotex Inc., 2011 U.S. Dist. LEXIS 125859; Par Pharm., Inc., v. TWi Pharms., Inc.,
773 F.3d 1186, 1189 (Fed. Cir. 2014).
91. TWi Pharms., Inc., 773 F.3d at 1196.
92. See id. at 1200.
93. See infra Part II.
94. Apotex Inc., 2011 U.S. Dist. LEXIS 125859, at *5–9, 64. For the purposes of this Note, only the
court’s invalidity holding under 35 U.S.C. § 103(a) will be discussed. Again, pharmacokinetics refers to
what the body does to a drug once administered. Jennifer Le, Overview of Pharmacokinetics, MERCK
MANUAL, https://www.merckmanuals.com/professional/clinical-pharmacology/pharmacokinetics/overvi
ew-of-pharmacokinetics [https://perma.cc/9VN8-8RDD] (Oct. 2020). In particular, pharmacokinetics
concerns the bioavailability of a drug within the body. Id.
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Reissue Patent No. 37,516 (RE’516 patent).95 The invalidity dispute
revolved around a claimed invention for smaller particles of modafinil,
a chemical compound with improved bioavailability and dissolution at
its target site.96 Apotex primarily argued that the RE’516 patent was
invalid because French company Laboratoire L. Lafon (Lafon) had
already invented the claimed subject matter. 97
U.S. Patent No. 4,177,290 (‘290 patent) was issued to Lafon on
December 4, 1979, which covered the chemical composition for
benzhydrylsulfinylacetamide, otherwise known as modafinil. 98 Later,
95. Apotex Inc., 2011 U.S. Dist. LEXIS 125859, at *6. An applicant who already has a patent seeks a
reissue patent where the claims in the previously granted patent are either too narrow or too broad. Id. at
*11 n.4. Filing a reissue patent puts the entire patent, including the original claims, at risk. Id.
96. Id. at *6–7; U.S. Patent No. RE37,516 (filed Apr. 1, 1999). Modafinil is a drug used to treat
sleepiness due to narcolepsy and other sleep–wake disorders. TEVA PHARMS. USA, INC., HIGHLIGHTS OF
PRESCRIBING INFORMATION: PROVIGIL® (2015).
97. Apotex Inc., 2011 U.S. Dist. LEXIS 125859, at *5. Cephalon purchased French company
Laboratoire L. Lafon (Lafon) on December 28, 2001, acquiring Lafon’s patent assets with that purchase.
Id. at *9.
98. Id.; U.S. Patent No. 4,177,290. The Lafon ‘290 patent titled, “Acetamide Derivatives” claims:
1. An acetamide derivative selected from the compounds of formula I

wherein ring a and ring b are each substituted zero, one or more times by
substituents selected from the group consisting of fluoro, chloro, bromo,
trifluoromethyl, nitro, amino, alkyl of 1 to 4 carbon atoms, inclusive, alkoxy of 1
to 4 carbon atoms, inclusive, and methylenedioxy; wherein Z is the radical
>CHSO—; and wherein A is selected from the group consisting of hydrogen, alkyl
of 1 to 4 carbon atoms, inclusive, hydroxyalkyl of l to 4 carbon atoms, inclusive,
and a group of formula R1 R2N—Y—wherein Y is a divalent linear or branched
chain hydrocarbon radical having 1 to 4 carbon atoms, inclusive, in the chain, and
R1 and R2, being the same or different, are selected from the group consisting of
hydrogen and alkyl of 1 to 4 carbon atoms, inclusive; and addition salts of the
compounds wherein A is a basic group.
2. A compound of claim 1 wherein A is R1R2 N—Y—wherein Y is a divalent linear
or branched chain hydrocarbon radical having 1 to 4 carbon atoms, inclusive, in the
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on May 22, 1990, U.S. Patent 4,927,855 (‘855 patent) was issued to
Lafon covering a method for the treatment of hypersomnia by
administering
a
therapeutic
composition
of
99
benzhydrylsulfinylacetamide. The ‘855 patent claims:
1. (—)-Benzhydrylsulfinylacetamide. 100
2. A method for the treatment of hypersomnia, which
comprises administering, to a patient in need of such a
treatment, an effective amount of a pharmaceutical
composition
consisting
essentially
of
(-)101
benzhydrylsulfinylacetamide as an arousing agent.
On April 8, 1997, U.S. Patent No. 5,618,845 (‘845 patent) was
issued to Cephalon covering modafinil in the form of acetamide
derivative having a defined particle size and was reissued to Cephalon
in 2002 as RE’516, which claims:
A pharmaceutical composition comprising a substantially
homogenous mixture of modafinil particles, wherein at least
95% of the cumulative total of modafinil particles in said
composition have a diameter of less than about 200 microns
(µm).102

chain, and R1 and R2, together with the N atom to which they are attached, form a
group selected from the group consisting of dimethylamine and diethylamine.
3. A compound of claim 1 wherein rings a and b are both unsubstituted and A is
hydrogen, and pharmacologically acceptable acid addition salts thereof.
4. A compound of claim 1 which is benzhydrylsulphinylacetamide.
5. A pharamaceutical [sic] composition having activity on the central nervous
system and consisting of, as an essential active ingredient, an active amount of a
compound of claim 1.
6. The compound of claim 1, wherein Z is—CHSO—and A is hydrogen, alkyl of 1
to 4 carbon atoms or hydroxyalkyl of 1 to 4 carbon atoms.
‘290 Patent.
99. U.S. Patent No. 4,927,855, at [45], [75] (filed Jan. 28, 1987). The ‘855 patent term expired on
April 22, 2010. Id.
100. Id. at col. 7, l. 19.
101. Id. at col. 7, ll. 20–24.
102. Apotex Inc., 2011 U.S. Dist. LEXIS 125859, at *7 (emphasis added); U.S. Patent No. 5,618,845
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In reconciling the ‘290 and ‘855 patents with the RE’516 patent, the
Federal Circuit grappled with whether the biological effect resulting
from a reduced particle size was inherently disclosed in prior art. 103
Cephalon nearly rests its entire case on the argument that “it
discovered the significance of improved bioavailability and
dissolution . . . [at a] smaller particle size, which is a [feature] Lafon
never appreciated.”104 Although the ‘290 and ‘855 patents failed to
include any reference to particle size, both parties stipulated to the fact
that Lafon “evaluated the effect of small[-]particle modafinil on
narcoleptic patients” from 1989 to 1991.105 Notably, one of the
modafinil batches from these clinical studies had 99.8% of particles
less than 206.36 microns, which is within the range of the RE’516
patent.106 The court noted that Cephalon’s argument “ignores the fact”
that Lafon “previously tested, manufactured[,] and used
[modafinil] . . . for the treatment of narcolepsy” and that
“Lafon . . . was aware of the compound’s chemical structure and
particle size . . . .”107 Ultimately, the court held that there are “no
differences” between Cephalon’s claimed invention and the
information communicated to Cephalon by Lafon because Cephalon’s
“‘discovery’ of the 220 micron [therapeutic] threshold” describes an
inherent property of modafinil. 108
Importantly, the court noted in dicta that “[h]ad Lafon not measured
particle size, Cephalon’s argument may carry more weight.”109 In
c. 10, ll. 49–53 (filed Oct. 6, 1994) (emphasis added); U.S. Patent No. RE37,516 E col. 10, ll. 49–53 (filed
Apr. 1, 1999).
103. Apotex Inc., 2011 U.S. Dist. LEXIS 125859, at *17–18.
104. Id. at *8 (emphasis omitted).
105. Id. at *17–18. From October 1989 to June 1991, Lafon conducted a clinical study that “evaluated
the effect of small[-]particle modafinil on narcoleptic patients.” Id. at *17. Lafon then conveyed its particle
size analysis to Cephalon in a memo dated November 10, 1993. Id. at *18.
106. Id. at *18.
107. Id. at *57–58.
108. Id. at *58, *67–69. Because modafinil was a widely known chemical compound for the treatment
of narcolepsy, combined with Cephalon’s possession of the compound and all the subsequent
communications with Lafon concerning that compound, “a person skilled in the art would have been
motivated to measure the particle size of modafinil as part of the FDA process, which requires such
information for the approval of new drug substances.” Id. at *67. As a result, the court found that the
“scope of the prior art [as] . . . a pharmaceutical composition of modafinil API having 95% of its particles
with a diameter less than 220 microns.” Id. at *67–69.
109. Apotex Inc., 2011 U.S. Dist. LEXIS 125859, at *57.
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holding that improved dissolution and bioavailability were inherent
properties of a reduction in particle size, the court relied almost
exclusively on Cephalon’s claim that a composition of modafinil had
the same particle size that Lafon previously disclosed and tested. 110
Notably, the court concluded that improved pharmacokinetics, which
resulted from a smaller particle size, fail to overcome an inherent
obviousness analysis where the pharmacokinetic properties were
previously known in the art (as the Lafon ‘290 and ‘855 patents) but
not necessarily related to a particular particle size. 111
This case implies that biological or pharmacokinetic properties
resulting from a reduced particle size ultimately fail an inherency
analysis unless the resulting biological or pharmacokinetic properties
were previously unknown or unseen in the prior art. 112 The court
placed importance on the fact that Lafon previously measured particle
size and recorded the different sizes that clinical trials were conducted
at.113 Even though Cephalon claimed a composition of smaller-sized
modafinil particles, modafinil was nevertheless previously tested and
recorded, which suggests that Lafon was at least aware of differences
in pharmacokinetic or biological properties associated with different
particle sizes.114 Further, Cephalon used the same composition of
modafinil as a basis to patent a specific particle size, despite the fact
that the claimed particle size was previously tested and disclosed by
Lafon.115 Accordingly, because the composition of modafinil is
physically the same, it follows that its properties must also be the
same.116

110. Id. at *65–69. Cephalon claimed particles less than 200 microns while Lafon disclosed particles
less than 206.36 microns, which was “within” the claimed range of the RE’516 patent. Id. at *18, *28.
Notably, Lafon disclosed the particle size(s) it tested, but the facts fail to indicate Lafon communicated
any improved dissolution or bioavailability at the smaller size. See id. at *18–20. The improved
pharmacokinetics comprised the inherency component at issue. See id. at *31.
111. See id. at *65–69.
112. See id.
113. Id. at *57–58, *63–64.
114. See id. at *57–58.
115. Apotex Inc., 2011 U.S. Dist. LEXIS 125859, at *58
116. See id. at *62; see also In re Spada, 911 F.2d 705, 708 (Fed. Cir. 1990) (“Products of identical
chemical composition can not have mutually exclusive properties.”).
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Nevertheless, the court only evaluated Cephalon’s microparticles in
the context of a composition patent. 117 So whether Cephalon’s
microparticles may overcome an inherent obviousness test in the
context of a method patent covering the treatment of narcolepsy is a
claim-drafting exercise that remains untouched by the courts.
B. Par Pharmaceutical, Inc. v. Twi Pharmaceuticals, Inc.: The Test
for Inherent Properties of Nanopharmaceuticals but Not the
Answer
In Par Pharmaceutical, Inc. v. TWi Pharmaceuticals, Inc., the
Federal Circuit established a heightened standard for inherent prior art
disclosures in the context of an obviousness analysis.118 Although the
Federal Circuit laid out the proper test for establishing inherency in the
context of obviousness, the court implies that something more than
reduced particle size, even on the nanoscale, is needed for a finding of
nonobviousness.119
Whether modifications in nanoparticle size render a claimed
invention inherent was touched upon in Par Pharmaceutical.120 In this
case, Par Pharmaceutical (Par) received approval to market a generic
micronized megestrol formulation of Megace OS, a synthetic
progestin medication used as an appetite stimulant to treat wasting
syndromes associated with cancer, HIV/AIDS, and anorexia.121
Megace OS exerts its appetite-stimulating effects when taken with
food, a problematic limitation for patients who take the drug for an

117. Apotex Inc., 2011 U.S. Dist. LEXIS 125859, at *67–68.
118. Par Pharm., Inc., v. TWi Pharms., Inc., 773 F.3d 1186, 1195–96 (Fed. Cir. 2014).
119. Id. at 1196.
120. Id.
121. Id. at 1188–89; see Lee Schacter, Marcel Rozencweig, Renzo Canetta, Susan Kelley, Claude
Nicaise & Laurie Smaldone, Megestrol Acetate: Clinical Experience, 16 CANCER TREATMENT REVS. 49,
57–58, 60 (1989) (discussing Megestrol acetate’s effect on anorexia, cachexia, and weight loss associated
with AIDS). Megestrol was traditionally used to treat wasting (body weakening) in cancer patients. TWi
Pharms., Inc., 773 F.3d at 1188. But in 1993, micronized megestrol was introduced to the market as
Megace OS for the treatment of anorexia and cachexia in AIDS patients. Id. at 1189. Specifically,
Micronized Megace OS helped to improve appetite, treat unexplained weight loss, and encourage weight
gain. Id. at 1190.
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illness that makes food difficult to consume, like an eating disorder. 122
Par experimented with micronized megestrol and subsequently
“reformulat[ed] the drug by reducing the particle size from the
micrometer range to the nanometer range.”123 The megestrol
nanoparticles exhibited “a greatly reduced food effect” relative to
micronized Megace OS, prompting Par to file a patent application for
its nanosized megestrol formulation. 124 The USPTO granted Par U.S.
Patent No. 7,101,576 (‘576 patent) covering methods for use of
nanosized megestrol formulations to “increas[e] the body mass in a
human patient suffering from anorexia, cachexia, or loss of body
mass.”125 Par subsequently began marketing its megestrol nanoparticle
122. See Sandra F. Simmons, Ph.D., Kathleen A. Walker & Dan Osterweil, M.D., The Effect of
Megestrol Acetate on Oral Food and Fluid Intake in Nursing Home Residents: A Pilot Study, 6 J. AM.
MED. DIRS. ASS’N S5, S10 (2005), https://www.sciencedirect.com/science/article/abs/pii/S1525861005
002033 [https://perma.cc/XQP6-DKSG]. Results from one comparative study indicate that Megace OS
significantly impacts food and fluid intake “only under the optimal mealtime feeding assistance
condition,” indicating that Megace OS is “not an effective nutritional intervention” to increase food during
a fasting state. Id. at S5 (emphasis added).
123. TWi Pharms., Inc., 773 F.3d at 1189. Par also contracted with a third party (Alkermes) “to use its
‘NanoCrystal’ technology to formulate [its] nanosized megestrol.” Id.
124. Id. A drug’s food effect describes changes in the drug’s rate and extent of absorption when
administered orally with food. JULIEN ET AL., supra note 34, at 6–7. Patients taking Megace OS with a
meal showed a “significantly higher rate and extent of absorption” compared to those who took Megace
OS without a meal. TWi Pharms., Inc., 773 F.3d at 1189. Yet, the nanosized megestrol formulation
showed a reduced food effect, which means that more of the drug remained in circulation longer. See id.
In any event, patients taking the nanosized megestrol formulation showed improved efficacy and a
“greatly reduced food effect[,]” suggesting that nanosized megestrol does not need to be taken with food.
See id. Because nanosized megestrol works equally as effective whether taken with or without food, the
drug is even more useful for illnesses that make consuming food difficult, like eating disorders. See id.
125. Nanoparticulate Megestrol Formulations, U.S. Patent No. 7,101,576 B2 col. 43 ll. 15–17; TWi
Pharms., Inc., 773 F.3d at 1188 (first alteration in original). Claim 1 of Par’s granted patent is as follows:
A method of increasing the body mass in a human patient suffering from anorexia,
cachexia, or loss of body mass, comprising administering to the human patient a
megestrol formulation, wherein:
(a) the megestrol acetate formulation is a dose of about 40 mg to about 800
mg in about a 5 mL dose of an oral suspension;
(b) the megestrol acetate formulation comprises megestrol particles having
an effective average particle size of less than about 2000 nm, and at least one
surface stabilizer associated with the surface of the megestrol particles; and
(c) the administration is once daily;
wherein after a single administration in a human subject of the formulation there is
no substantial difference in the Cmax of megestrol when the formulation is
administered to the subject in a fed versus a fasted state[,] . . . wherein fasted state
is defined as the subject having no food within at least the previous 10 hours, and
wherein fed state is defined as the subject having a high-calorie meal within

Published by Reading Room, 2022

25

Georgia State University Law Review, Vol. 38, Iss. 3 [2022], Art. 14

1082

GEORGIA STATE UNIVERSITY LAW REVIEW

[Vol. 38:3

formulation as Megace ES, which “was indicated for use ‘without
regard to meals . . . .’”126
TWi Pharmaceuticals (TWi) filed an abbreviated new drug
application (ANDA) with the FDA to market a generic form of
nanosized megestrol. 127 Then, Par brought suit against TWi for
infringement of its nanosized megestrol formulation. 128 TWi countered
the infringement claims by stating that claims toward its nanosized
megestrol formulation in the ‘576 patent were invalid as obvious in
light of prior art that disclosed a micronized megestrol formulation. 129
TWi supported its invalidity arguments by citing the label of Megace
OS, which disclosed micronized oral suspensions of megestrol used to
“treat[] . . . anorexia, cachexia, and unexplained weight loss [in] AIDS
patients.”130 In addition, TWi offered U.S. Patent No. 5,399,363 (‘363
patent) and U.S. Patent No. 5,145,684 (‘684 patent) as prior art against
the Par ‘576 patent and argued that it would be obvious to use
nanosized megestrol formulations for the treatment of anorexia. 131

approximately 30 minutes of dosing.
U.S. Patent No. 7,101,576 B2 col. 43 ll. 15–31, 37–41 (emphasis added).
126. TWi Pharms., Inc., 773 F.3d at 1189–90.
127. See id. at 1190.
128. Id. Parties submit an abbreviated new drug application (ANDA) to the FDA to expedite approval
of generic drugs. Abbreviated New Drug Application (ANDA), FDA, https://www.fda.gov/drugs/typesapplications/abbreviated-new-drug-application-anda [https://perma.cc/8DFS-FWRU] (Jan. 14, 2022).
129. TWi Pharms., Inc., 773 F.3d at 1190. The Federal Circuit notes that two general categories of prior
art were disputed: (1) pharmacokinetic properties of megestrol and (2) use of nanotechnology in drug
formulation. Id. TWi cited Megace OS as “demonstrat[ing] that micronized oral suspensions of megestrol
were [previously] used . . . [to] treat[] . . . anorexia, cachexia, and unexplained weight loss [in] AIDS
patients.” Id.
130. Id.
131. Id. at 1191. Both patents teach “the use of the NanoCrystal technology for [making] . . . drug
particles less than either 1000 nm or 400 nm in size.” Id. The ‘363 patent listed megestrol as one of the
anticancer agents to use with the nanotechnology, while the ‘684 patent teaches that nanoparticle
technology could lead to greater bioavailability and a more rapid onset of action. Id. Nonetheless, TWi
relied on the Megace OS label to disclose micronized megestrol for the treatment of “anorexia, cachexia,
and unexplained weight loss for AIDs patients” and a study by Kathleen K. Graham et. al. to disclose
dose-dependent weight gain in patients who took micronized megestrol. Id. at 1190; Kathleen K. Graham,
Dennis J. Mikolich, Alvan E. Fisher, Marshall R. Posner & Michael N. Dudley, Pharmacologic
Evaluation of Megestrol Acetate Oral Suspension in Cachectic AIDS Patients, 7 J. ACQUIRED IMMUNE
DEFICIENCY SYNDROMES 580, 580–86 (1994). TWi argued that the combination of the ‘684 patent, the
‘363 patent, the Megace OS label, and the Graham study disclosed each and every element of Par’s
claimed invention. TWi Pharms., Inc., 773 F.3d at 1190–91. Because the combination of prior art
references “failed to disclose a known food effect in [nanosized] megestrol, both TWi and the [] court
rel[ied] on the doctrine of inherency to disclose the food effect limitation.” Id. at 1194.
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Both the District and Federal Circuit courts sought to answer the
question of whether “[t]he reduced food effect was thus ‘an inherent
result’ of nanosized megestrol ‘even if it was previously not known in
the prior art that a food effect existed.’”132
The district court found the ‘576 patent obvious in light of the
Megace OS label and disclosures in the prior art, ‘363 patent, and ‘684
patent, concluding that the lack of a food effect in nanosized megestrol
was an inherent property of micronized megestrol. 133 But the district
court ignored the scope of the functional limitation at issue by failing
to determine whether a reduction in particle size naturally resulted in
“no substantial difference” in food effect as claimed. 134 In fact, TWi’s
expert testified that improved bioavailability “necessarily results in a
decrease in any food effect . . . .”135 TWi used this expert testimony,
coupled with general evidence that smaller particle size improves
bioavailability, to support its argument that nanosized megestrol’s
improved bioavailability is an inherent property of micronized
megestrol.136 “[P]er the district court, the reduced particle size would,
ipso facto, lead to a reduced food effect.”137 Such “broad diktats
132. TWi Pharms., Inc., 773 F.3d at 1192 (quoting Par Pharm., Inc. v. TWi Pharms., Inc., No.
CCB-11-2466, 2014 U.S. Dist. LEXIS 21704, at *46 (D. Md. Feb. 21, 2014), vacated sub nom. Par
Pharm., Inc. v. TWi Pharms., Inc. 773 F.3d 1186 (Fed. Cir. 2014)).
133. Id.
134. Id. at 1196 (“While it may be true that a reduction in particle size naturally results in some
improvements in the food effect, the district court failed to conclude that the reduction in particle size
naturally results in ‘no substantial difference’ in the food effect.” (emphasis omitted) (quoting In re
Oelrich, 666 F.2d 578, 581 (C.C.P.A. 1981))). See generally Megan Leinen Johns, Federal Circuit
Clarifies Inherency Doctrine in Reversing Obviousness Determination, FINNEGAN (Jan. 2015),
https://www.finnegan.com/files/Upload/Newsletters/Last_Month_at_the_Federal_Circuit/2015/January/
FCN_Jan15_Print.pdf [https://perma.cc/V4YA-PDE3] (analyzing TWi Pharms., Inc. case).
135. TWi Pharms., Inc., 773 F.3d at 1196. Essentially, TWi’s expert testified that a person with ordinary
skill or knowledge in the subject area would know a decrease in particle size increases bioavailability. See
id. Moreover, the court in Apotex made clear that a person with ordinary skill or knowledge in the subject
area knows that decreasing particle size increases bioavailability. Apotex Inc. v. Cephalon, Inc., No.
06-cv-2768, 2011 U.S. Dist. LEXIS 125859, at *30–31 (E.D. Pa. Nov. 7, 2011), aff’d, 500 F. App’x 959
(Fed. Cir. 2013).
136. See TWi Pharms., Inc., 773 F.3d at 1196.
137. Id. For example, claim one in the ‘576 patent “requires ‘no substantial difference in [the] Cmax’
between the fed and fasted states.” Id. (quoting U.S. Patent No. 7,101,576 B2 col. 42 l. 67–col. 43 l. 1).
The court continues, “[w]hile it may be true that a reduction in particle size naturally results in some
improvement in the food effect, the district court failed to conclude that the reduction in particle size
naturally results in ‘no substantial difference’ in the food effect.” Id. (quoting In re Oelrich, 666 F.2d at
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[concerning] the effect of particle size on bioavailability and food
effect” fail to even correspond with the actual limitations at issue. 138
Accordingly, the Federal Circuit vacated the district court’s decision
and held that the district court applied an incorrect inherency standard
in its obviousness analysis. 139 The Federal Circuit cautioned that “the
concept of inherency must be limited when applied to
obviousness . . . .”140 Because the record provided insufficient
evidence that TWi met the high standard for inherency in the
obviousness context, the court clarified that inherency is “present only
when the limitation at issue is the ‘natural result’ of the combination
of prior art elements.”141 Merely reciting a newly discovered function
or property inherently present in the prior art does not distinguish a
claim drawn to those properties. 142
The Federal Circuit’s holding raises several important
considerations. First, the Federal Circuit’s inherent obviousness
analysis seems to directly contradict the inherent obviousness analysis
in In re Huai-Hung Kao.143 That case involved an invention directed
581). The “claimed” food effect is “no substantial difference in Cmax[.]” Id. (emphasis omitted). The Cmax
is the maximum serum concentration a drug achieves at its target site within the body. See Tracy, supra
note 25, at 49. Accordingly, the claimed food effect limitation has no substantial difference in drug
concentration at the target site, which is a critical step missing from the district court’s analysis. TWi
Pharms., Inc., 773 F.3d at 1196.
138. Twi Pharms., Inc., 773 F.3d at 1196. “[T]he limitation at issue necessarily must be present, or the
natural result of the combination of elements explicitly disclosed by the prior art.” Id. The district court
failed to meet this “high” standard because it failed to even require TWi to present evidence on point and
sufficient to prove inherency. Id. at 1195–96. TWi provided expert testimony that an improvement in
bioavailability “necessarily results in a decrease in any food effect,” combined with evidence “that a
reduction in particle size improves bioavailability.” Id. at 1196.
139. Id. at 1188, 1196 (remanding “for the district court to determine if TWi has presented clear and
convincing evidence that demonstrates the food effect as claimed is necessarily present in the prior art
combination”).
140. Id. at 1195.
141. Id. at 1195–96 (emphasis added) (quoting In re Oelrich, 666 F.2d at 581); see Johns, supra note
134. In essence, the record provided evidence that TWi never met its burden in demonstrating that Par’s
claimed food effect limitations were necessarily present in combination of elements from the prior art.
TWi Pharms., Inc., 773 F.3d at 1196; see Johns, supra note 134.
142. See TWi Pharms., Inc., 773 F.3d at 1196. On remand, the district court held the food effect
limitations were “necessarily . . . present, or the natural result of the combination of elements explicitly
disclosed by the prior art” and the Federal Circuit subsequently affirmed. Par Pharm., Inc. v. TWi Pharms.,
Inc., 120 F. Supp. 3d 468, 470–71 (D. Md.), aff’d per curiam, 624 F. App’x 756 (Fed. Cir. 2015) (Rule
36 affirmance).
143. Compare TWi Pharms., Inc., 773 F.3d at 1196 (requiring limitation to be present to rely on inherent
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to a method of treating pain that recited food effect limitations like
TWi, but instead claimed a “Cmax . . . about 50% higher
when . . . administered to the subject under fed versus fasted
conditions.”144 There, the Federal Circuit held that the claims were
inherently obvious, reasoning that the “claimed ‘food effect’ is an
inherent property of oxymorphone itself, present both in controlled
release and immediate release formulations of that drug.”145 This
apparent inconsistency might reflect the differences in particular
quantitative specificity. 146 For example, In re Huai-Hung Kao
involved a patent which effectively claimed a particular
pharmaceutical concentration, while TWi involved a patent which
claimed a particular pharmaceutical particle size. 147 Pharmaceutical
concentration is closely related to improved bioavailability and
pharmacokinetic effects, which the disputed patent in In re Huai-Hung
Kao effectively claimed.148 Because the Federal Circuit was inclined
to reach an opposite result in TWi, the court likely viewed new or novel
pharmacokinetic properties resulting from a decreased particle size to
be more ambiguous in the literature than pharmacokinetic properties
resulting from a change concentration alone. 149
Second, because the Federal Circuit was unable to determine
whether a reduction in particle size naturally results in no substantial
difference in food effect, the court implies that a claim favors
obviousness), with In re Huai-Hung Kao, 639 F.3d 1057, 1070 (Fed. Cir. 2011) (not requiring limitation
to be present to find substantial evidence for inherent obviousness).
144. In re Kao, 639 F.3d at 1064 (emphasis omitted) (quoting U.S. Patent Application No. 12/167,859
claim 8). The Cmax refers to the maximum serum concentration a drug achieves at a particular target after
administration of the first dose but before administration of a second dose. Tracy, supra note 25, at 49. In
simpler terms, the Cmax refers to the maximum amount of a drug found in the blood. Id.
145. In re Kao, 639 F.3d at 1070.
146. See id.; TWi Pharms., Inc., 773 F.3d at 1195–96.
147. In re Kao, 639 F.3d at 1061, 1063–64; TWi Pharms., Inc., 773 F.3d at 1189–90.
148. See In re Kao, 639 F.3d at 1063. The patent at issue in In re Kao was directed to a method of
treating pain by administering a controlled release formulation of oxymorphone. Id. The claimed method
“(1) provides at least 12 hours of sustained pain relief and (2) results in a ‘Cmax’ (maximum
concentration) at least about 50% higher” when given to patient in a fed versus fasting state. Id. at 1063–
64. Taken together, the sustained effect (“12 hours of sustained pain relief”) and the high Cmax (maximum
concentration 50% higher in fed versus fasting patients, which indicates that more of the drug reached its
final destination point in fed patients) suggests that the disputed patent claimed a particular pharmaceutical
concentration and its subsequent biological effects. Id.
149. See TWi Pharms., Inc., 773 F.3d at 1196 (“[T]he reduced particle size would, ipso facto, lead to a
reduced food effect.”).
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nonobviousness when the claim’s body recites inherent properties with
quantitative specificity. 150 But the Federal Circuit’s holding appears to
directly contradict the outcome in Apotex Inc., where reciting the
inherent property with quantitative specificity in the body of the claim
failed to save Cephalon’s patent from a finding of invalidity. 151 These
differences may be reconciled by the weight placed on prior art that
disclosed the same particle size that Cephalon attempted to patent,
while Par relied on the court’s construction of the term “nanoparticle”
to differentiate its megestrol from micronized megestrol
formulations.152
Interestingly, both Par and Cephalon argued for patent validity
based on the premise that improved pharmacokinetics were
undisclosed in the prior art in either case. 153 Nevertheless, the contrary
outcomes in the two cases might be attributable to the differences in
statutory subject matter claimed. The disputed patent in Par
Pharmaceutical claimed a method of treatment while the disputed
patent in Apotex Inc. claimed a chemical composition.154 For the
150. Id.
151. See Apotex Inc. v. Cephalon, Inc., No. 06-cv-2768, 2011 U.S. Dist. LEXIS 125859, at *5, *57–58
(E.D. Pa. Nov. 7, 2011), aff’d, 500 F. App’x 959 (Fed. Cir. 2013); U.S. Patent No. 5,618,845; U.S. Reissue
Patent No. RE37,516 E col. 10, ll. 51–53 (“[M]odafinil particles in said composition have a diameter less
than about 200 microns (µm).” (emphasis added)). The court held that the improved biological effect was
inherent in the prior art and the decreased particle size was obvious where the prior patent owner tested
the compound at various particle sizes, including the claimed size. Apotex Inc., 2011 U.S. Dist. LEXIS
125859, at *57–58, *67–68.
152. See, e.g., Apotex, Inc., 2011 U.S. Dist. LEXIS 125859, at *57–58; TWi Pharms., Inc., 773 F.3d at
1197.
153. Apotex, Inc., 2011 U.S. Dist. LEXIS 125859, at *65–66; see also TWi Pharms., Inc., 773 F.3d at
1196.
154. TWi Pharms., Inc., 773 F.3d at 1188–89; Apotex Inc., 2011 U.S. Dist. LEXIS 125859, at *6–7.
When claiming a composition, like a chemical compound, patentability depends upon the specific
composition materials, not on the method or process of making or mixing those materials. See 35
U.S.C. § 101; see also KAYE SCHOLER LLP, supra note 47 (“Researchers . . . can potentially obtain
patents on particular forms of the active compound even if the compound itself is known to the person of
ordinary skill.”). Chemical compounds “are generally claimed by specifying the compound’s molecular
formula . . . and . . . structure.” Id. For example, water would be claimed using its molecular formula
(H2O) and its structure:
O
/\
H H
Id. Likewise, for a method claim, patentability depends upon the specific steps listed and may be limited
by the materials used to carry out the steps recited by the particular method or process. U.S. PAT. &
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method of treatment claim, TWi in Par Pharmaceutical failed to
provide evidence that improved bioavailability was a result of the
claimed food effect limitation flowing from nanosized particles, so
there was no way for the court to conclude that no food effect
necessarily flowed from decreased particle size and improved
bioavailability.155 In contrast, Lafon provided evidence that it
previously tested the smaller particle size Cephalon claimed. 156 That,
coupled with the fact Cephalon claimed a chemical structure identical
to the one Lafon previously patented, rendered the properties of that
structure inherent.157
Moreover, the opposing outcomes in Par Pharmaceutical and
Apotex, Inc. might be attributable to the differences in general particle
size scale. In Apotex, Inc., although Cephalon claimed smaller
modafinil particles than the modafinil particles patented by Lafon,
both modafinil formulations nevertheless exist at the microscale, just
at different sizes on the same scale. 158 In effect, the Federal Circuit
provides some hope in Par Pharmaceutical that decreasing particle
size from microscale to nanoscale at least deserves to be reviewed
under a higher standard in the context of an obviousness analysis.159
C. The Future of Nanopharmaceutical Patent Litigation After Par
Pharmaceutical
Par Pharmaceutical highlights a recent trend in the context of
pharmaceutical and nanopharmaceutical patent litigation. Although
patent litigation concerning nanotechnology has been relatively
limited thus far, “[i]f genetics are a litmus test for emerging medical
technologies, then developments and inventions in nanotechnology
(and nanopharmaceuticals specifically) will soon be appearing [more
frequently] in court dockets.”160 The current “messy” and
“fragmented” nanotech-related patent landscape is already blocking
TRADEMARK OFF., supra note 10, § 2106.03, at 2100-20 (A method or process is “a mode of treatment of
certain materials to produce a given result.”).
155. TWi Pharms., Inc., 773 F.3d at 1196.
156. Apotex Inc., 2011 U.S. Dist. LEXIS 125859, at *54–55.
157. Id. at *58.
158. Id. at *8.
159. TWi Pharms., Inc., 773 F.3d at 1195–96.
160. Paradise, supra note 4, at 182.
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novel nanoparticle patents and possesses the ability to cause extended
legal battles and potentially stall nanotechnology’s development, as
seen in the cases discussed above. 161 Patent blocking, and its
associated legal battles, alone poses the biggest threat to
commercialization.162
This patent blocking is characterized by unduly broad patents,
making it “almost certain” that nanotech-related patent enforceability
will be a “major problem” in the future as companies attempt to sort
out who owns what patent right. 163 Accordingly, patent owners are
likely to challenge the validity of competing patents to determine who
has the best claim to each patent right. And one ever-increasing
method to challenge pharmaceutical patent validity is through an
inherent obviousness argument. 164 But despite the Federal Circuit
cautioning lower courts to limit its application of the inherency
doctrine to obviousness inquiries, the court’s holding nevertheless
reaffirms inherent obviousness as a tool for alleged infringers and the
USPTO to challenge patent validity.165
D. Inherent Obviousness After Par Pharmaceutical
“Anticipation by inherency is a well-recognized, and generally
well-understood, patent law doctrine.”166 On the other hand,
161. Bawa, supra note 6, at 728. In the context of inherency, patent blocking is likely the result of
overclaiming, which refers to the practice of drafting overly broad patent claims. See id. at 728–29 n.144.
Patent thickets are another way new patents may be blocked. Id. at 728–29, 728 n.144. Patent thickets are
characterized as a “dense web of overlapping intellectual property rights” that make it difficult to
commercialize new technology. Id. at 728 n.144 (quoting Richard Raysman & Peter Brown, Patent
Cross-Licensing in the Computer and Software Industry, N.Y. L.J., Jan. 11, 2005, at 3, 6). These patent
thickets naturally block new patents from the patent landscape and subsequently discourage innovation.
Id. at 728–29 n.144.
162. Bawa, supra note 6, at 729.
163. Id. at 729, 731.
164. See generally Paul W. Browning, Ph.D., William B. Raich, Ph.D. & Paul Townsend, Inherency in
Obviousness—A
Worrying
Trend?,
FINNEGAN
(Apr.
13,
2018),
https://www.finnegan.com/print/content/64398/Inherency-in-ObviousnessA-Worrying-Trend.pdf?q=
[https://perma.cc/K4KM-KFVY] (discussing inconsistencies in applying inherent obviousness).
165. Id.; see Par Pharm., Inc. v. TWi Pharms., Inc., 773 F.3d 1186, 1196 (Fed. Cir. 2014); Apotex Inc.
v. Cephalon, Inc., No. 06-cv-2768, 2011 U.S. Dist. LEXIS 125859, at *66–68 (E.D. Pa. Nov. 7, 2011),
aff’d, 500 F. App’x 959 (Fed. Cir. 2013).
166. Browning et al., supra note 164, at 1; see Daniel P. O’Brien & W. Murray Spruill, Does Inherency
Have a Place in Determinations of Obviousness?, 32 BIOTECHNOLOGY L. REP. 3, 3, 6, 13 (2013).
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obviousness by inherency is confusing and has led to “improper
applications” of the doctrine in lower courts.167 This confusion arises
from the fact that “[a]nticipation focuses on what [was] disclosed in
the prior art” while obviousness focuses on what a person with
“ordinary skill in the art . . . understood or appreciated based on that
disclosure.”168 Obviousness encompasses what was known at the time
of invention—thus, hindsight is forbidden.169 Yet this prohibition on
hindsight directly conflicts with the principle of inherency, which
permits later recognition of unknown properties that existed at the time
of the invention.170 Because confusion lingers over the precise scope
of applying inherency in the context of an obviousness analysis,
litigants have increasingly attempted to invoke inherent obviousness
arguments.171
III. PROPOSAL
The Federal Circuit’s holding in Par Pharmaceutical highlights
ambiguities surrounding the inherency doctrine when used as a sword
to challenge nanopharmaceutical patents. 172 Although the Federal
Circuit laid out the appropriate test for inherency in the context of an

167. Browning et al., supra note 164, at 2.
168. Id. at 1; see O’Brien & Spruill, supra note 166, at 3, 13–14, 16. “[A] prior art disclosure may
inherently disclose a claim element even where a person [with] ordinary skill [or knowledge] in the art
would not have recognized that inherent element at the time of invention.” Browning et al., supra note
164, at 1–2. Accordingly, this represents the existing nuance present in inherent anticipation, as compared
to inherent obviousness. See id.
169. Browning et al., supra note 164, at 2; O’Brien & Spruill, supra note 166, at 6.
170. See Brassica Prot. Prods. LLC v. Sunrise Farms (In re Cruciferous Sprout Litig.), 301 F.3d 1343,
1349 (Fed. Cir. 2002) (“Inherency is not necessarily coterminous with the knowledge of those of ordinary
skill in the art. Artisans of ordinary skill may not recognize the inherent characteristics or functioning of
the prior art.” (first quoting MEHL/Biophile Int’l Corp. v. Milgraum, 192 F.3d 1362, 1365 (Fed. Cir.
1999); and then quoting Atlas Powder Co. v. IRECO Inc., 190 F.3d 1342, 1347 (Fed. Cir. 1999))).
171. See, e.g., Browning et al., supra note 164, at 2; Par Pharm., Inc. v. TWi Pharms., Inc. 773 F.3d
1186, 1195–96 (Fed. Cir. 2014); Apotex Inc. v. Cephalon, Inc., No. 06-cv-2768, 2011 U.S. Dist. LEXIS
125859, at *66–68 (E.D. Pa. Nov. 7, 2011), aff’d, 500 F. App’x 959 (Fed. Cir. 2013); Honeywell Int’l Inc.
v. Mexichem Amanco Holding S.A. de C.V., 865 F.3d 1348, 1354–55 (Fed. Cir. 2017); Endo Pharms.
Sols., Inc. v. Custopharm Inc., 894 F.3d 1374, 1381 (Fed. Cir. 2018) (“Obviousness cannot be predicated
on what is unknown.” (quoting In re Shetty, 566 F.2d 81, 86 (C.C.P.A. 1977))).
172. See generally TWi Pharms., Inc., 773 F.3d 1186 (vacating district court’s decision because it did
not analyze, in its inherency decision, whether TWi proved that the claimed food effect was necessarily
present in the prior art).
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obviousness analysis, the court’s silence concerning the proper scope
of that test foreshadows inevitable delays at the commercialization
stage while companies hash out their patent rights in court. 173 Further,
litigation might financially compromise future research and
development by companies and research institutions in the business of
designing cutting-edge nanotechnology products, such as
nanoparticles. Accordingly, the courts and the USPTO alike should
refrain from relying on inherent obviousness to invalidate or prevent
biological or chemical patents.
A. Eliminating the Concept of Inherency in the Context of an
Obviousness Analysis in Courts and at the USPTO
When considering the precise nature of chemical and biological
patents, courts and the USPTO should avoid applying the inherency
doctrine to these “poorly[] understood . . . inventions.”174 The
confusing and seemingly contradictory nature of inherency in the
context of obviousness has necessarily prompted practitioners and
legal scholars to demand its eradication entirely. 175
The Federal Circuit in Par Pharmaceutical established the
heightened standard for applying inherency in an obviousness
analysis, but this standard ultimately fails to keep up with the scientific
advancement of poorly understood inventions, especially those
concerning nanotechnology. 176 Combined with the Federal Circuit’s
holding in Honeywell International Inc. v. Mexichem Amanco Holding
S.A. de C.V., the standard for inherent obviousness seems to be: if a
173. See Bawa, supra note 6, at 728–29.
174. Paul G. Alloway, Note, Inherently Difficult Analysis for Inherent and Accidental Biotechnology
Inventions, 38 SUFFOLK U. L. REV. 73, 77 & n.33 (2004) (“[G]iven the particular problems associated
with . . . inventions for which technological understanding is limited, . . . courts should apply less
stringent requirements for holding patent claims . . . inherent[] . . . .”); see also Jeffrey Coleman,
“Undetected, Unsuspected, and Unknown”: Should We Anticipate Problems for Scientific Innovation
Following Schering Corp. v. Geneva Pharmaceuticals?, 82 FORDHAM L. REV. 165, 195 (2013) (discussing
commentators who warn that the inherency anticipation doctrine may discourage innovation and
undermine the goals of patents).
175. See Janice M. Mueller & Donald S. Chisum, Enabling Patent Law’s Inherent Anticipation
Doctrine, 45 HOUS. L. REV. 1101, 1102, 1107 (2008) (proposing a narrower interpretation of inherent
anticipation such that it would eliminate analysis of inherent obviousness); see also Coleman, supra note
174, at 204.
176. TWi Pharms., Inc., 773 F.3d at 1195–96.
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combination of prior art elements naturally results in an unknown
property, then that property is inherent unless the opposing party
shows it was unexpected.177 Pharmaceutical and nanoparticle patents
are notably susceptible to this inherency analysis, presumably because
the Federal Circuit’s standard effectively crosses off pharmacokinetic
effects as an inherent result of new pharmaceutical formulations. 178
Moreover, the current standard discounts the fundamentally different
biological effects that a nanopharmaceutical composition might
exhibit in response to structural changes, such as particle size.179
Science is moving faster today than courts can keep up with. For
instance, researchers have already developed a fully autonomous DNA
robotic system designed to seek and destroy solid tumors and
vascularized metastases. 180 Researchers aim to use this same DNA
robotic system as a precise drug-delivery platform for treating
additional diseases by modifying the geometry of nanostructures, the
targeted grouping, and the loaded cargoes. 181 What if changing a
nanostructure’s geometry results in remarkable pharmacokinetic
improvements and overall patient experience, but nevertheless
succumbs to subsequent inherency challenges? Inherent obviousness
acts as a weapon to the rapidly expanding base of scientific and
nanotechnological knowledge by preventing scientists from putting
their ideas into practice and by stalling research institutions from
putting those reduced ideas on the market. 182 In light of nanoscale
drug-delivery research’s critical importance to society and the quickly
177. Honeywell Int’l Inc. v. Mexichem Amanco Holding S.A. de C.V., 865 F.3d 1348, 1355 (Fed. Cir.
2017) (“What is important regarding properties that may be inherent, but unknown, is whether they are
unexpected.”). But, resting the inherency standard on whether the resulting properties are unexpected
conflicts with obviousness, which is based on what a person having ordinary skill in the art knew at the
time of invention. See TWi Pharms., Inc., 773 F.3d at 1196; see also Sanjeev Mahanta, Ph.D., J.D.,
Inherency in Obviousness – What Is the Correct Standard?, IPWATCHDOG (Aug. 1, 2017),
https://www.ipwatchdog.com/2017/08/01/inherency-obviousness-correct-standard/
[https://perma.cc/D33G-BS85].
178. See Browning et al., supra note 164, at 2 (discussing several cases regarding pharmaceutical
patents where the Federal Circuit discussed inherency in obviousness).
179. See KAYE SCHOLER LLP, supra note 47.
180. Ariz. State Univ., Cancer-Fighting Nanorobots Programmed to Seek and Destroy Tumors,
PHYS.ORG (Feb. 12, 2018), https://phys.org/news/2018-02-cancer-fighting-nanorobots-tumors.html
[https://perma.cc/EXA4-JLFB].
181. Id.
182. See MUELLER, supra note 62, at 231.
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advancing base of scientific knowledge, inherent obviousness should
be eradicated entirely when evaluating the validity of pharmaceutical
and nanopharmaceutical patents.
The underlying policy furthered by recognizing obviousness is to
limit patent protection to subject matter that is truly nonobvious, which
turns on whether a person having ordinary skill in the art would know
to combine the prior art references to make the invention. 183 But when
an inherent property is “secret,” or unknown in the prior art, how
would an inventor know to combine the prior art references in a way
to produce the claimed invention?184
For example, consider a hypothetical drug A. Drug A was patented
in 1995 and has since been used as a general anticancer medication.
Publication B was released in 2010 and discloses the general
contention that smaller particles can cross the blood-brain barrier.
Drug C was subsequently produced for the first time in 2020. Drug C
is similar to drug A, except that drug C was reproduced on the
nanoscale using crystallography. But drug C demonstrates a
remarkable pharmacokinetic effect at the nanoscale: improved ability
to cross the blood-brain barrier and penetrate reproductive cancer cells
in the brain because of drug C’s increased bioavailability.185
Under the current inherent obviousness standard, a patent for drug
C will likely be invalidated because the combination of references
discloses an increase in bioavailability as an inherent result of a
nanoparticle’s ability to cross the blood-brain barrier. The possibility

183. Id. at 229–30.
184. 3 R. CARL MOY, MOY’S WALKER ON PATENTS § 9.28 (4th ed.), Westlaw (database updated Dec.
2020) (noting that secret events shall be excluded from prior art because inclusion “hold[s] the patentee
responsible for knowing things that are in fact unknowable”).
185. The blood-brain barrier is a highly selective semipermeable layer of endothelial cells that protects
against solutes in circulating blood from nonselectively entering the extracellular fluid of the central
nervous system (where neurons reside). See generally Richard Daneman & Alexandre Prat, The
Blood-Brain Barrier, 7 COLD SPRING HARBOR PERSPS. BIOLOGY 1 (2015) (discussing what the
blood-brain barrier is and observing how penetrating the blood-brain barrier is common in several diseases
and in therapeutics). When a drug crosses the blood-brain barrier, its bioavailability necessarily increases.
See Rodrigo Marmo da Costa e Souza, Inaê Carolline Silveira da Silva, Anna Beatriz Temoteo Delgado,
Pedro Hugo Vieira da Silva & Victor Ribeiro Xavier Costa, Focused Ultrasound and Alzheimer’s
Disease: A Systematic Review, 12 DEMENTIA & NEUROPSYCHOLOGIA 353, 356–57 (2018) (“[S]mall
lipid-soluble molecules with less than 400 Daltons (6.64 x 10-19 milligrams) in weight . . . can cross the
BBB unassisted . . . .”).
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of this finding is sufficient to disincentivize pharmaceutical companies
from exploring more specified applications of preexisting
medications.186
Accordingly,
the
valuable
nature
of
nanopharmaceutical research demands that either the Federal Circuit
eradicate any consideration of inherent obviousness in the context of
biological or chemical patents or Congress eradicate the concept of
inherent obviousness.
B. Tools to Use Instead of Inherent Obviousness
Although eliminating inherent obviousness in the context of
biological or chemical patents means that patentees will likely prevail
against the USPTO or accused infringers at a higher rate, it does not
follow that patentees will always prevail. 187 Nor does it follow that the
patent landscape will become overly saturated with biological or
chemical patents. 188 Rather, accused infringers simply need to rely on
other tools to challenge patent validity. 189
1. Inherent Anticipation
Inherent anticipation is used to supply a claim limitation that is
necessarily present in a single prior art reference but may be
unknown.190 The inherency principle seeks to prevent patenting an
invention that was already available to the public and thus cannot be
truly novel.191 Inherent obviousness, however, differs from inherent
anticipation because no single prior art reference teaches the claimed
invention; thus, that claimed invention was not practiced in the prior

186. See ROBERT A. WEINBERG, THE BIOLOGY OF CANCER 869–70 (2d ed. 2014) (“[T]ruly successful
clinical outcomes and durable clinical responses will depend in the future on the development of
multi-drug therapies . . . .”); see also id. at 871 sidebar 16.6 (“[E]conomic forces . . . create disincentives
for pharmaceutical companies to test their own proprietary drugs in combination with those produced by
their competitors. Patent regulations have also discouraged . . . uses of patented compounds by firms that
are in direct competition with the patent holders.”).
187. See Bawa et al., supra note 5, at 4; Mueller & Chisum, supra note 175, at 1157.
188. See Bawa et al., supra note 5, at 4.
189. See id.
190. See O’Brien & Spruill, supra note 166, at 13.
191. Mahanta, supra note 177.

Published by Reading Room, 2022

37

Georgia State University Law Review, Vol. 38, Iss. 3 [2022], Art. 14

1094

GEORGIA STATE UNIVERSITY LAW REVIEW

[Vol. 38:3

art.192 Because anticipation permits retrospect and does not turn on
what a person having ordinary skill in the art knew at the time of
invention, the doctrine of inherency should be limited to the contours
of anticipation.193
Moreover, limiting inherency to the context of an anticipation
analysis eliminates the issue surrounding what a person with ordinary
skill or knowledge in the art recognized at the time of invention. 194
Anticipation permits retroactive recognition of a feature unknown at
the time of invention.195 By contrast, obviousness does not, and should
not, permit such retroactive recognition because an unknown or
unrecognized feature can hardly be obvious.196 Accordingly, relying
on inherent anticipation to capture those elements not expressly
disclosed in prior art avoids the unnecessary determination of whether
a seemingly unknown or inherent feature in the prior art might be
obvious in light of that disclosure. 197
2. Plain Old Obviousness
Rather than relying on prior art to supply missing claim limitations,
courts and accused infringers should perform the fact-intensive
obviousness inquiry.198 An obviousness inquiry requires courts to
consider evidence such as “the level of ordinary skill in the pertinent
art[,]” “reasonable expectation of success . . . in combining . . . the
prior art” references, whether the prior art “teach[es] away” from the
claimed invention, and objective indicia such as commercial success
and failure of others, among others. 199 In addition, under the U.S.
Supreme Court’s interpretation of obviousness in KSR International
Co. v. Teleflex Inc., “courts [may] consider whether an invention
192. Id.
193. See Irah Donner, Anticipation by Inherency, WILMERHALE (Nov. 14, 2003),
https://www.wilmerhale.com/en/insights/publications/anticipation-by-inherency-november-14-2003
[https://perma.cc/39KC-3FGQ].
194. See id. (“[A] prior art source may anticipate even if one of ordinary skill would not have recognized
the inherent features in the prior art.”).
195. See Mueller & Chisum, supra note 175, at 1157.
196. See id.
197. See id.
198. See id.
199. Id.
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would have been obvious from the perspective of a [person having
ordinary skill in the art] endowed with ‘common sense’ . . . .”200
Accordingly, these obviousness factors “permit a . . . rich[] analysis of
patent validity”; thus, the scope of obviousness should not extend
beyond the metes and bounds of what was expressly disclosed in the
combination of prior art references. 201
CONCLUSION
Cases like Par Pharmaceutical exhibit the rather harsh stance the
Federal Circuit has taken when considering whether a patentee’s
claimed invention should fall under the catch-all invalidation umbrella
known as inherent obviousness.202 As a result of the Federal Circuit’s
decision in Par Pharmaceutical, accused infringers have increasingly
attempted to use inherent obviousness as a shield for their own alleged
infringing activities.203 Biological and chemical patents are especially
susceptible to inherency challenges where a pharmaceutical
composition’s novel and “nonobvious” feature is a discovery or
improvement in pharmacokinetics. 204 In light of the expanding field of
nanotechnology and the promising benefit that nanoparticulate
formulations offer in comparison to conventional drugs, the law needs
to adapt in a way that will incentivize pharmaceutical companies to
continue developing targeted drug-delivery systems by way of
nanoparticles. Eliminating the concept of inherent obviousness in the
context of biological or chemical patents is a good place to start.

200. Id. (quoting KSR Int’l Co. v. Teleflex, Inc., 550 U.S. 398, 421 (2007)); see also KSR Int’l Co.,
550 U.S. at 421 (“A person of ordinary skill is also a person of ordinary creativity, not an automaton.”).
201. Mueller & Chisum, supra note 175, at 1157; see KSR Int’l Co., 550 U.S. at 421.
202. See generally Mahanta, supra note 177 (discussing confusion with inherent obviousness); Donner,
supra note 193 (discussing inherent anticipation); MUELLER, supra note 62, at 229–30 (discussing
inherent anticipation); Mueller & Chisum, supra note 175 (arguing for narrower interpretation of inherent
anticipation to remove inconsistencies in framework); Coleman, supra note 174 (discussing
inconsistences in caselaw regarding inherent anticipation).
203. See Browning et al., supra note 164, at 2.
204. Id. at 2, 3.
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